索他洛尔治疗剂量对华法令抗凝药效的相关性研究  

Study on the correlation between therapy dosage of soltalol and effective dosage of warfarin

作　　者：刘辉[1] 张彦周[1] 郝静[1] 邹汇菲[1] 康瑜[1] 毛家亮[1] 何奔[1] 

机构地区：[1]上海交通大学医学院附属仁济医院心内科,上海市200000

出　　处：《实用诊断与治疗杂志》2007年第6期404-405,共2页Journal of Practical Diagnosis and Therapy

摘　　要：目的：探讨索他洛尔治疗剂量和华法令药效的相关性,为临床安全规范地应用华法令抗凝治疗提供预测依据,以期能增强抗凝疗效并减少其不良反应。方法：年龄60-75岁门诊和住院心房颤动患者46例,均应用索他洛尔、华法令和单用华法令两阶段,采用自身对照研究治疗剂量索他洛尔对达到标准抗凝强度所需华法令剂量的影响。结果：治疗剂量索他洛尔不影响达标抗凝强度的华法令所需量,两者差异无统计学意义（P〉0.05）。结论：心房颤动患者加用或停用索他洛尔无需对凝血酶原时间的国际标准化率（INR）值重新评估监测。Objective To provide basis for clinicians to apply warfarin effectively and avoid the drug adverse effects by studying the correlation between the therapy dosage of soltalol and effective dosage of warfarin. Methods Forty-six atrial fibrillation patients were divided into two groups to compare the dosage of warfarin. Group A was treated with both soltalol and warfarin and group B was treated with warfarin only. Results To sustain the satisfied INR, the dosages of warfarin in different stage didn＇t reach statistical significance between two groups （P〉0. 05）. Conclusion For the atrial fibrillation patients,soltalol has no influence on the effect of warfarin. There is no need to re-test the INR while adding or withdrawing soltalol.

关 键 词：索他洛尔 华法令 心房颤动 

分 类 号：R541.75[医药卫生—心血管疾病]